Chandan Healthcare

Chandan Healthcare allotted 5,99,998 equity shares at Rs 234 each, aggregating to about Rs 14.04 crore, upon conversion of an equivalent number of fully convertible warrants issued on a preferential basis. Jeena Sikho Lifecare Limited took 4,50,000 of the shares, while Compact Structure Fund and three individuals took the remainder, with all five allottees classed as public holders. The allotment took issued capital to 2,50,52,062 shares, leaving 16,50,002 warrants with the five holders plus a further 22,00,000 warrants with other holders exercisable by August 2027. The company earned about Rs 177 crore of consolidated revenue in FY24 and Rs 82.26 crore in the June quarter, including Rs 49.75 crore of standalone diagnostics revenue. It listed in early 2025 after a fresh issue of about Rs 70.42 crore earmarked for a Lucknow flagship centre and two central reference labs scheduled for September 2026 commissioning.

Powered by Tijori

Chandan Healthcare's board recommended that shareholders appoint Sanjay Srivastava, a retired Additional Commissioner of Uttar Pradesh State GST, as an independent director for five years from 30 September 2026. It approved annual remuneration of ₹1.25 lakh plus taxes and expenses for Rahul Jain & Associates as cost auditor for FY27, subject to shareholder ratification. The board proposed shifting ₹50 crore of unutilised proceeds from 44.5 lakh convertible warrants, approved in November 2025, from acquisitions to new diagnostic laboratories and comprehensive diagnostic centres, with the other warrant terms unchanged. Diagnostics generated ₹49.75 crore of standalone revenue in the first quarter of FY27, while the company's network reached 327 centres, including 264 franchises. Its FY27 plan included eight comprehensive centres and more than six laboratory or radiology centres.

Powered by Tijori

Chandan Healthcare said it had taken a strategic decision to exit its pharmacy business and focus its resources on diagnostics. It presented consolidated FY26 revenue of ₹280.67 crore, EBITDA of ₹56.84 crore and profit after tax of ₹27.06 crore, followed by Q1 FY27 total income of ₹82.26 crore, EBITDA of ₹20.98 crore and PAT of ₹7.50 crore. The company described an exclusive diagnostics partnership with JSL, an Ayurvedic healthcare provider, to serve partner hospitals and clinics across 15 states and more than 100 cities. It outlined plans for two PET-CT centres in Uttar Pradesh and a clinical genomics laboratory in Lucknow. Pharmacy represented 42.8% of FY26 core vertical sales, while pathology and radiology accounted for 40.95% and 16.25%, respectively; receivables and inventory had risen 49% and 71% by December 2024 from March 2024.

Powered by Tijori

April 2 (Reuters) - Chandan Healthcare Ltd CAND.NS:

• CHANDAN HEALTHCARE LTD - BUYS NISHKAM IMAGING IN NEW DELHI

Source text: ID:nNSE8qFqD6

Further company coverage: CAND.NS

(([email protected];))

March 20 (Reuters) - Chandan Healthcare Ltd CAND.NS:

• CHANDAN HEALTHCARE LTD - SECURES TENDER FOR 1.5 TESLA MRI SYSTEM AT CIVIL HOSPITAL ROHTAK

Source text: ID:nNSE6vJjJn

Further company coverage: CAND.NS

(([email protected];))

March 18 (Reuters) - Chandan Healthcare Ltd CAND.NS:

• COMMENCED DIAGNOSTIC OPERATIONS IN KOTA, RAJASTHAN

Source text: ID:nnAZN4SLVHL

Further company coverage: CAND.NS

(([email protected];))

March 2 (Reuters) - Chandan Healthcare Ltd CAND.NS:

• CHANDAN HEALTHCARE LTD - AWARDED 10-YEAR PPP PROJECT IN PUNJAB

• CHANDAN HEALTHCARE LTD - PROJECT FOR RADIOLOGY CENTRES WITH COST 2.50 BILLION RUPEES IN 10 YEARS

Source text: ID:nNSEbRDd0W

Further company coverage: CAND.NS

(([email protected];))

Jan 19 (Reuters) - Chandan Healthcare Ltd CAND.NS:

• CHANDAN HEALTHCARE LTD - AWARDED 10-YEAR PPP PROJECT IN PUNJAB

• CHANDAN HEALTHCARE LTD - PROJECT COST ESTIMATED AT 260 MILLION RUPEES

Source text: ID:nNSE4TwlSB

Further company coverage: CAND.NS

(([email protected];))

Jan 9 (Reuters) - Chandan Healthcare Ltd CAND.NS:

• STARTS DIAGNOSTIC OPERATIONS IN PUNJAB

Source text: ID:nNSE1llzkQ

Further company coverage: CAND.NS

(([email protected];))

Oct 10 (Reuters) - Chandan Healthcare Ltd CAND.NS:

• APPROVED ISSUE OF CONVERTIBLE EQUITY WARRANTS FOR UPTO UPTO 1.04 BILLION RUPEES

Source text: ID:nNSE1xFdJY

Further company coverage: CAND.NS

(([email protected];;))